Another year of growth for La Capitale

News - La Capitale was once again able to balance growth and profitability in 2013 and even surpass some of the ambitious goals set in its five-year strategic plan. "On the eve of its 75th anniversary, the company is stronger, more stable, and performing better than ever," declared René Rouleau, Chairman and Chief Executive Officer of La Capitale Civil Service Mutual during the Annual General Assembly held in Quebec City on April 7, 2014.

Atrium Innovations announces management transition

News - Atrium Innovations announces that Pierre Fitzgibbon, President and CEO of Atrium, will step down from the Company in 2014, by mutual agreement with the Board of Directors. Mr. Fitzgibbon will remain President and CEO while the Board conducts a search for his replacement and will continue to be one of Atrium's largest individual shareholders after his departure.

The Entrepreneurs: PetalMD prognosis good

News - Patrice Gilbert was convinced that the free network of online time management and communication services for physicians he launched four years ago would be a hit with Canadian doctors.

EXFO acquires ByteSphere's technologies to extend its service assurance offering in infrastructure performance visibility for mobile and fixed networks

News - EXFO announced today it has acquired the assets of ByteSphere LLC, a privately held software company in the Boston area that specializes in global IT management and network monitoring solutions.

Merck Canada announces $2-million grant to support personalized treatment in cancer

News - At the 6th Annual National Conference to Defeat Cancer, organized by Coalition Priorité Cancer, Merck Canada reinforced the company's continued commitment to the Quebec life sciences research innovation sector by announcing a $2-million grant to the Quebec - Consortium de recherche en oncologie clinique (Q-CROC).

Commendations: National Optics Institute (INO): The leader in generating technological innovation in Canada

News - Still buzzing from the festivities surrounding its 25th anniversary, National Optics Institute (INO) is proud to announce it has been recognized not once but twice in a study commissioned by the Saskatchewan Research Council (SRC).

An oral tritherapy that restores walking in paraplegics

News - Crowdfunding campaign for a Quebec-based company developing a tritherapy that can restore 'on-demand' walking for 45 min in experimental models of complete paralysis, wich is being tested in patients.

EXFO Launches Powerful, Compact Next Generation Multimodule Platform

News - EXFO announced today the launch of the FTB-2 Pro Compact Platform, the industry's smallest platform for high speed, multi-technology and optical testing. This is the next generation in the FTB line of portable test platforms and the newest and most advanced member of the EXFO platform family.

Aeterna Zentaris to Present Poster on New Therapeutic Opportunities in Oncology with Erk Inhibitors at AACR Meeting in San Diego

News - Aeterna Zentaris today announced that a poster will be presented on AEZS-134, a highly potent and selective ATP competitive Erk inhibitor, during the American Association for Cancer Research (AACR) Annual Meeting, which will be held April 5-9, 2014 in San Diego, California.

Aeterna Zentaris Announces Effectiveness of $50 Million Shelf Registration Statement for “At-the-Market” Common Share Issuance Programs

News - Aeterna Zentaris today announced that its shelf registration statement on Form F-3 previously filed with the Securities and Exchange Commission has been declared effective by the SEC. Under the shelf registration statement, the Company may offer and sell from time to time, in one or more public offerings in the United States, up to $50 million of common shares in one or more "at-the-market" distribution programs, during a 36-month period. The specifics of any particular ATM share issuance program, along with the terms and the use of proceeds of any such common shares offered by the Company will be determined at the time of any such offering and will be described in detail in a prospectus supplement or supplements filed with the SEC at the time of any such offerings.


Subscribe to our newsletter for interesting news and information.

Print this page